Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 5/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.38 |
| ▸ | CDK9 | P50750 | 3/20 | 0.38 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312951 | 0.81 | DYRK3 (0.37) | DYRK1ADYRK2CCNA2CDK2CDK5 | |
| SCHEMBL5389145 | 0.76 | CLK4 (0.41) | — | |
| SCHEMBL5396378 | 0.76 | NR1H4 (0.41) | DYRK1ADYRK2CCNA2CDK2CDK5 | |
| SCHEMBL5385383 | 0.76 | NMT1 (0.39) | DYRK1ADYRK2CCNA2CDK2CDK5 | |
| SCHEMBL8312732 | 0.76 | NMT1 (0.33) | DYRK1ADYRK2CCNA2CDK2CDK5 | |
| SCHEMBL5389869 | 0.73 | FYN (0.37) | FYN | |
| SCHEMBL5406662 | 0.71 | GPR52 (0.46) | DYRK1ADYRK2CCNA2CDK2CDK5 | |
| SCHEMBL5097619 | 0.71 | KMT2A (0.40) | FYNNR1H4 | |
| SCHEMBL5393535 | 0.69 | ASIC1 (0.43) | DYRK1ADYRK2NMT1FYNF2RL3 | |
| SCHEMBL5406388 | 0.68 | NMT1 (0.37) | DYRK1ADYRK2CCNA2CDK2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271191-B2 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2007-09-18 | — | — | US | disclosed |
| US-7271191-B2 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2007-09-18 | — | — | US | disclosed |
| US-7271191-B2 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20060264474-A1 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease | MERCK SHARP & DOHME LTD. (GB) | 2006-11-23 | — | — | US | disclosed |
| WO-2004089911-A1 | PYRAZOLE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS USEFUL IN THE TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264474-A1 | Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | DYRK1A 4646/4885DYRK2 4509/4885CCNA2 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.